药品详细

Procainamide(普鲁卡因胺)

基本信息
剂型规格
适应症
药理
临床
理化性质
相互作用
文档
专利
Pathway
文献
序列

化学结构式图

中文名

普鲁卡因胺

英文名

Procainamide

分子式

C₁₃H₂₁N₃O

化学名

4-amino-N-[2-(diethylamino)ethyl]benzamide

分子量

Average: 235.3253
Monoisotopic: 235.168462309

CAS号

51-06-9

ATC分类

C01B 未知

药物类型

small molecule

阶段

approved

商品名

同义名

基本介绍

A derivative of procaine with less CNS action. [PubChem]

生产厂家

Apothecon inc div bristol myers squibb
King pharmaceuticals inc
Panray corp sub ormont drug and chemical co inc
Parke davis div warner lambert co
Parkedale pharmaceuticals inc

封装厂家

E.R. Squibb and Sons LLC
Hospira Inc.
Ivax Pharmaceuticals
Kaiser Foundation Hospital
Major Pharmaceuticals
Mckesson Corp.
Monarch Pharmacy
Murfreesboro Pharmaceutical Nursing Supply
Neuman Distributors Inc.
PD-Rx Pharmaceuticals Inc.
Physicians Total Care Inc.
United Research Laboratories Inc.

参考

Synthesis Reference	Not Available
General Reference	Not Available

剂型

规格

化合物类型

Type	small molecule

Classes

Benzoyl Derivatives
Benzamides

Substructures

Amino Ketones
Aliphatic and Aryl Amines
Benzene and Derivatives
Carboxylic Acids and Derivatives
Aromatic compounds
Carboxamides and Derivatives
Benzoyl Derivatives
Benzamides
Anilines

适应症

药理

Indication

For the treatment of life-threatening ventricular arrhythmias.

Pharmacodynamics

Procainamide is an agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Procainamide appears to be similar to that of procaine and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected.

Mechanism of action

Procainamide is sodium channel blocker. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.

Absorption

75 to 95%

Volume of distribution

2 L/kg

Protein binding

15 to 20%

Metabolism

Hepatic

Important The metabolism module of DrugBank is currently in beta. Questions or suggestions? Please contact us.

Substrate	Enzymes	Product
Procainamide	Cytochrome P450 2D6	N-Acetyl-3-hydroxyprocainamide	Details

Route of elimination

Trace amounts may be excreted in the urine as free and conjugated p-aminobenzoic acid, 30 to 60 percent as unchanged PA, and 6 to 52 percent as the NAPA derivative.

Half life

~2.5-4.5 hours

Clearance

Not Available

Toxicity

LD₅₀=95 mg/kg (rat, IV); LD₅₀=312 mg/kg (mouse, oral); LD₅₀=103 mg/kg (mouse, IV); LD₅₀=250 mg/kg (rabbit, IV)

Affected organisms

Humans and other mammals

Pathways

Pathway	Name	SMPDB ID
	Procainamide (Antiarrhythmic) Pathway	SMP00324

理化性质

Properties

State

solid

Experimental Properties

Property	Value	Source
melting point	165-169 °C	Not Available
water solubility	5050 mg/L	Not Available
logP	0.88	HANSCH,C ET AL. (1995)
pKa	9.32	SANGSTER (1994)

Predicted Properties

Property	Value	Source
water solubility	3.02e+00 g/l	ALOGPS
logP	1.42	ALOGPS
logP	0.95	ChemAxon
logS	-1.9	ALOGPS
pKa (strongest acidic)	15.75	ChemAxon
pKa (strongest basic)	9.04	ChemAxon
physiological charge	1	ChemAxon
hydrogen acceptor count	3	ChemAxon
hydrogen donor count	2	ChemAxon
polar surface area	58.36	ChemAxon
rotatable bond count	6	ChemAxon
refractivity	72.25	ChemAxon
polarizability	27.69	ChemAxon

药物相互作用

Drug	Interaction
Amiodarone	Amiodarone may increase serum levels and toxicity of procainamide.
Artemether	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Cimetidine	The histamine H2-receptor antagonist, cimetidine, may increase the effect of procainamide.
Ciprofloxacin	Ciprofloxacin may increase the effect of procainamide.
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Dihydroquinidine barbiturate	Quinidine increases the effect of procainamide
Donepezil	Possible antagonism of action
Fingolimod	Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.
Galantamine	Possible antagonism of action
Levofloxacin	Levofloxacin may increase the effect of procainamide.
Lumefantrine	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Mesoridazine	Increased risk of cardiotoxicity and arrhythmias
Ofloxacin	Ofloxacin may increase the effect of procainamide.
Quinidine	Quinidine increases the effect of procainamide
Quinidine barbiturate	Quinidine increases the effect of procainamide
Ranitidine	The histamine H2-receptor antagonist, ranitidine, may increase the effect of procainamide.
Ranolazine	Possible additive effect on QT prolongation
Rivastigmine	Possible antagonism of action
Tacrolimus	Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
Telavancin	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Terbinafine	Terbinafine may reduce the metabolism and clearance of Procainamide. Consider alternate therapy or monitor for therapeutic/adverse effects of Procainamide if Terbinafine is initiated, discontinued or dose changed.
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Thioridazine	Increased risk of cardiotoxicity and arrhythmias
Thiothixene	May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
Toremifene	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
Trimethoprim	Trimethoprim may reduce the clearance of Procainamide. Alternative treatments should be considered. If Trimethoprim is initiated or the dose is increased, monitor for increased toxicity of Procainamide (e.g. QTc intervals, EKG, serum drug concentrations). If Trimethoprim is discontinued or the dose decreased, monitor for reduced effects of Procainamide.
Trimipramine	Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
Vardenafil	Increased risk of cardiotoxicity and arrhythmias
Voriconazole	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Vorinostat	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Ziprasidone	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
Zuclopenthixol	Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).

食物相互作用

Avoid alcohol.
Take with food to reduce irritation.

返回 | 收藏